{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"179","value":"162"},{"groupId":"OG001","spread":"392","value":"533"},{"groupId":"OG002","spread":"1020","value":"1520"}]}],"title":"Cycle 1 (N = 27, 34, 7)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"288","value":"456"},{"groupId":"OG001","spread":"655","value":"866"},{"groupId":"OG002","spread":"701","value":"1150"}]}],"title":"Cycle 2 (N = 3, 13, 5)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Blinatumomab serum concentrations were quantified in all patients during the first 2 treatment cycles in the phase 1 part of the study only. Blinatumomab concentrations were quantified using a validated bioassay, the lower limit of quantification was 50 pg/mL. Steady state serum concentration (Css) was presumed on day 1, approximately 5 half-lives after the start of the IV infusion.\n\nThe steady state serum concentration reported is the mean of the observed concentrations collected after during cycles 1 and 2.","dispersionType":"Standard Deviation","groups":[{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 5 µg/m²/day.","id":"OG000","title":"Phase 1: Blinatumomab 5 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 15 µg/m²/day.","id":"OG001","title":"Phase 1: Blinatumomab 15 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 30 µg/m²/day.","id":"OG002","title":"Phase 1: Blinatumomab 30 µg/m²/Day"}],"paramType":"MEAN","populationDescription":"Phase 1 participants with available blinatumomab concentration data","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2 during the IV infusion on day 3 (at least 48 hours after start of infusion) and days 8, 15 and 22 (steady state) and day 29 at End of Infusion (EoI) and 2, 4, and 8 hours after EoI for ages ≥ 2 years.","title":"Steady State Concentration of Blinatumomab","type":"SECONDARY","unitOfMeasure":"pg/mL"}